Viewing nowCombinationDapaM Duo Extended Release Tablet 10/500 mg
Dapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aprogen Biosciences, Co., Ltd.

MFDS item code 202302656 · Approved 2023.09.06 · Insurance code 645210850
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to help control blood sugar in adults with Type 2 diabetes by combining dapagliflozin and metformin. When taken in conjunction with diet and exercise, it can improve blood sugar control. Specifically, for patients whose blood sugar is not adequately controlled and have cardiovascular disease or risk factors, it is important to refer to expert guidance on the impact of dapagliflozin on cardiovascular events. Overall, this medication is beneficial for blood sugar control and health improvement in patients with Type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience of antidiabetic drug therapy and in whom adequate glycemic control is difficult to achieve with monotherapy alone: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may result in altered glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used to control blood sugar. It can rarely cause a serious condition known as lactic acidosis, so patients with impaired kidney function, severe infections, dehydration, or heart problems should not use it. Also, caution is needed when used with insulin or sulfonylureas due to the risk of hypoglycemia. Patients with reduced kidney function or elderly patients, as well as those with decreased fluid volume, must evaluate kidney function and fluid status before administration and continuously monitor during treatment. Women who are pregnant or breastfeeding should not take this medication, nor should patients with genetic issues such as lactose intolerance. This medication may increase the risk of genital and urinary infections, so if symptoms of infection appear, consult a doctor immediately. Vitamin B12 deficiency may occur, so regular monitoring of blood vitamin B12 levels is recommended during long-term use. Excessive alcohol should be avoided while taking this medication, and if symptoms such as sudden weight loss, severe abdominal pain, vomiting, or shortness of breath occur, notify healthcare professionals immediately. In cases of surgery or radioactive iodine contrast tests, the medication should be stopped 48 hours prior to the test and can be resumed only after kidney function is confirmed to be normal. This medication may cause dehydration or hypotension, so particularly for elderly patients or those on diuretics, blood pressure and fluid status should be closely monitored. In case of overdose, seek medical attention immediately for appropriate treatment, and dialysis may be helpful if necessary. During treatment, dizziness or hypoglycemic symptoms may occur, so caution is advised when driving or operating machinery. Finally, this medication should be kept out of reach of children and stored in the original container to prevent misuse or degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to safely preserve the medication's efficacy.
Pink oblong extended-release film-coated tablet
28 tablets/box [7 tablets/PTP x 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aprogen Biosciences, Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.